Paramiway up 174%! Domestic oseltamivir to expand its leading advantages

According to the information released by the National Influenza Center, at present, influenza activities in the north and south of China are at the level of epidemic season, and are still on the rise At present, the characteristics of influenza virus have changed, and H3N2 subtype has been transformed to B subtype before entering autumn and winter season With the rapid development of medicine, people have improved their understanding of influenza virus Under the influence of the multiple factors of influenza virus antigen variability and acute respiratory virus infection, effective prevention is difficult, and antiviral treatment is still one of the main treatment programs At present, many countries have carried out the strategic reserve of anti influenza drugs As the best plan to resist the sudden outbreak of influenza, it objectively promotes the rapid development of anti influenza drug market According to the information released by the World Health Organization, there are about 600 million to 1.2 billion influenza cases every year in the world, including 3 million to 5 million severe influenza cases and 250000 to 500000 deaths due to influenza every year In recent years, influenza A (H1N1), a (H3N2) and B (influenza B) have spread all over the world, as well as h7n9 avian influenza and H5N1 and h5n8 highly pathogenic avian influenza viruses in South Korea, all of which threaten human health At present, the global anti influenza drugs are mainly Tamiflu of Roche, abidol of OJSC, Relenza of GlaxoSmithKline and laninamivir of Japan's first three co pharmaceuticals In 2016, the sales volume of the leading drug oseltamivir was 827 million US dollars, an increase of 12.67% over the previous year The scale of domestic sample hospitals is over 100 million yuan According to the data of menet HDM system, the market scale of anti influenza drugs, influenza vaccine and pneumonia vaccine in public hospitals in key cities in 2016 was over 80 million yuan, an increase of 65.67% over the previous year According to the data and market estimates in the first three quarters of 2017, the market scale of anti influenza drugs, influenza vaccine and pneumonia vaccine in public hospitals in key cities in China reached 112 million yuan, an increase of 37.15% over the previous year Domestic anti influenza drugs are mainly oseltamivir, paramivir, abidor, zanamivir and rimantadine 16 enterprises hold the registration number of anti influenza virus preparations According to the data of menet HDM system, according to the data and market estimates in the first three quarters of 2017, the market scale of anti influenza drugs in public hospitals in key cities in China reached 103.88 million yuan, an increase of 32.70% over the previous year Relatively speaking, the market share of anti influenza virus vaccine and pneumonia vaccine is relatively small In April 2017, Pfizer 13 pneumococcal polysaccharide conjugate vaccine "Peier 13" was listed in China, which led to the growth of this market It is estimated that the market scale of anti influenza virus vaccine and pneumonia vaccine in public hospitals in key cities in 2017 will reach 8 million yuan, an increase of 143.87% compared with the previous year, while the anti influenza virus vaccine only accounts for 40% of the market share Domestic oseltamivir shows outstanding performance Oseltamivir (oseltamivir) is a specific inhibitor of neuraminidase, which can inhibit the mature influenza virus from leaving the host cell, thus inhibiting the spread of influenza virus in human body It is the most effective antiviral drug for influenza A and B, which can control the course of influenza earlier in the infected, alleviate the high fever symptoms of patients, so as to prevent influenza virus and The harm of avian influenza virus to human cells and tissues In 1996, oseltamivir was R & D and listed by Gilead company and jointly developed and operated by Roche company after being transferred In 2001, oseltamivir entered China under the trade name of Tamiflu In 2005, the FDA approved oseltamivir as a drug to prevent influenza in children It has been sold in many countries around the world and is an important variety in the influenza prevention reserve Due to the close relationship with the epidemic of the disease, the sales market of oseltamivir is highly volatile So far, CFDA has approved the registration of four enterprises, including Roche of Switzerland, Roche pharmaceutical of Shanghai, three-dimensional pharmaceutical of Shanghai and the west, and Changjiang pharmaceutical of Yichang East sunshine, to produce oseltamivir phosphate, laying a solid foundation for the prevention and treatment of influenza outbreaks in China According to the data of menet HDM system, in 2016, the amount of oseltamivir used in public hospitals in key cities in China was 72.32 million yuan, an increase of 105.22% over the previous year, accounting for 92.41% of anti influenza drugs Kewei, Roche's Tamiflu and Shanghai's three-dimensional pharmaceutical industry accounted for 79.98%, 19.64% and 0.38%, respectively Covey has shown an increasing trend year by year, while Duffy and ORFI have shown mediocre performance According to the data and market estimates in the first three quarters of 2017, the market scale of oseltamivir, an anti influenza drug for public hospitals in key cities in China, has reached more than 92.8 million yuan, an increase of 28.40% over the previous year Under the situation of increasing domestic drug share year by year, the popularity and growth of clinical use of oseltamivir have been promoted Palamivir increased by 174.58%, while oseltamivir, rimantadine, zanamivir and abidor were not so good Palamivir was a rising star On April 5, 2013, CFDA approved the launch of the first class new anti influenza drug, palamivir injection, which was independently developed in China It is another new type of influenza virus NA inhibitor after the successful development of zanamivir and oseltamivir and its launch in 1999 According to the data of menet HDM system, in 2016, the market scale of the public hospitals in key cities in China was 3.54 million yuan, an increase of 500% over the previous year According to the data and market estimates in the first three quarters of 2017, the amount of drug used by the public hospitals in key cities in China was over 9.7 million yuan, an increase of 174.58% over the previous year Panamivir injection, the exclusive domestic product registered by Guangzhou Nanxin Pharmaceutical Co., Ltd., is a new type of anti influenza virus drug It has the fastest antipyretic time for influenza A and B viruses among neuraminidase inhibitors Its bioavailability is greater than 98% by intravenous injection In the face of the increasing frequency of influenza virus infection, palamivir injection provides patients with new treatment options.